Trending Aesthetic Treatments: What Patients Are Asking For

Daxxify (prabotulinumtoxinA-xvfs, Revance) and Xeomin are competing on duration claims, with Daxxify marketed at up to 6 months versus the standard 3–4 months for Botox and Dysport. The clinical reality: Daxxify's duration advantage is real in some patients but inconsistent; onset is slower (7–14 days vs. 3–7 days for traditional toxins). Patient demand exists, particularly among those fatigued by frequent appointments, but it's not universal. The financial model differs: Daxxify's per-unit cost is higher, and rebate structures (check Revance's Rewards program) may not match Allergan's Alle ecosystem. Xeomin, owned by Galderma, has gained traction partly as a resistance mitigation option—some practitioners rotate it in for patients showing antibody formation to Botox. The strategic question: durability appeals to a subset of your patient base (convenience-focused, often higher-income), but doesn't displace your core Botox volume. Test it as a premium upsell, not a replacement.

The FDA approval of RHA Redensity Eye (Revance/Teoxane) in 2026 created a new indication-specific filler for under-eye hollows—a problem zone that was previously addressed off-label with traditional hyaluronic acid fillers or biostimulators. RHA (Resilient Hyaluronic Acid) is a newer-generation HA with higher elasticity and lower crosslinking, designed to move with facial expression. The clinical advantage is real: it's softer, less likely to cause Tyndall effect (blue discoloration) in the thin periocular skin, and FDA-cleared for the indication. Patient demand is strong because under-eye hollowing is visible, aging, and difficult to address with topicals. Pricing: expect RHA Redensity Eye to command a premium over standard HA fillers (similar to how RHA Collection prices above Juvéderm). The owner consideration: this is a high-visibility, high-margin treatment that pairs well with neuromodulator visits. Add it to your filler portfolio if you're already doing periocular work; if not, the learning curve and injection technique are moderate. Check Revance's loyalty program (Revance Rewards) for rebate alignment.

Radiesse (calcium hydroxyapatite, Galderma) has seen renewed demand, partly driven by the GLP-1 weight-loss drug phenomenon. Patients losing significant weight via semaglutide or tirzepatide experience volume loss in the face, and biostimulators like Radiesse (and PLLA products such as Sculptra) are ideal for rebuilding lost collagen and structure. Radiesse works immediately (it's a volumizer) and stimulates collagen over 12–24 months, making it a bridge treatment for post-weight-loss patients. Galderma's H1 2026 earnings explicitly cited a 25% boost in aesthetics sales driven by GLP-1 demand. The financial model: Radiesse is priced per syringe (typically higher than HA fillers) and often requires multiple sessions. Patient lifetime value is high because these patients are motivated and often return for maintenance. The owner play: position Radiesse (and Sculptra) as part of a post-weight-loss rejuvenation package. This is a growing patient cohort—market it explicitly to your GLP-1 patients and their referral networks.

Ellacor (Cytrellis), using proprietary micro-coring technology, recently expanded into Australia for full-body skin resurfacing. Micro-coring removes tiny columns of skin and stimulates collagen remodeling—it's less aggressive than traditional CO₂ laser resurfacing but more effective than microneedling for certain indications (acne scars, texture, sun damage). Ellacor's advantage is precision and reduced downtime compared to ablative lasers. Patient demand is growing, particularly among those seeking non-invasive or minimally invasive resurfacing. The owner consideration: this is a device-based treatment requiring capital investment and training. If you already own RF microneedling (Morpheus8, Secret RF) or fractional laser equipment, Ellacor competes for the same patient population and appointment slots. Evaluate your current device utilization before adding another platform. Pricing and reimbursement vary by geography; check FDA clearance status in your market.

Ultherapy PRIME (Merz), the first and only FDA-cleared ultrasound with real-time visualization for non-surgical skin lifting, recently gained a new indication for the knee—expanding beyond face and neck. Ultrasound-based lifting (focused ultrasound energy at depth) appeals to patients seeking non-invasive alternatives to surgical lifting. PRIME's real-time imaging is a competitive advantage, reducing operator variability. Patient demand for non-invasive body contouring and skin tightening is strong, especially as GLP-1 patients seek solutions for loose skin post-weight loss. The owner consideration: Ultherapy is a premium treatment with high per-session pricing but requires significant patient education (results develop over 2–3 months). It pairs well with injectables and resurfacing but demands dedicated appointment time. Capital cost is substantial; ensure you have sufficient patient volume to justify it. Check Merz's loyalty and rebate programs for alignment with your other product lines.

Allergan Aesthetics (AbbVie) refreshed its APP (Allergan Partner Program) loyalty program, adding quarterly Botox rebates for qualifying growth—a direct incentive to increase volume. Evolus (Jeuveau) posted strong Q2 2026 results with accelerating revenue growth and raised guidance, signaling competitive pricing and rebate pressure. Galderma's record H1 2026 sales ($3.134 billion, +24.6% YoY) reflect both market expansion and aggressive rebate strategies. The owner implication: loyalty programs are now a material part of your per-unit economics. Track your rebate tier across Alle (Allergan), Aspire (Galderma), and Evolus Rewards. Quarterly rebates tied to volume growth incentivize you to push specific products. Understand the threshold: if you're near a rebate cliff, a small volume increase can materially improve margin. Conversely, if you're below a tier, the rebate structure may not justify switching. Model this into your treatment mix and packaging decisions.